Asio Capital LLC Boosts Stock Holdings in Elevance Health, Inc. $ELV

Asio Capital LLC grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 16.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,457 shares of the company’s stock after buying an additional 2,979 shares during the quarter. Elevance Health accounts for 1.1% of Asio Capital LLC’s portfolio, making the stock its 28th largest position. Asio Capital LLC’s holdings in Elevance Health were worth $7,522,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Artisan Partners Limited Partnership lifted its holdings in shares of Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC raised its holdings in shares of Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after purchasing an additional 798,457 shares during the last quarter. Brave Warrior Advisors LLC raised its holdings in shares of Elevance Health by 65.3% during the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock valued at $592,603,000 after purchasing an additional 724,349 shares during the last quarter. Baupost Group LLC MA raised its holdings in shares of Elevance Health by 114.1% during the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock valued at $426,195,000 after purchasing an additional 703,000 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its holdings in shares of Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock valued at $660,935,000 after purchasing an additional 627,038 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a 2.48% average Medicare Advantage/Part D rate increase for 2027, plus an estimated ~2.5% boost from risk‑adjustment changes (effective ~5% total), directly improving revenue and margin outlook for ELV. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Coverage pieces highlight ELV as a clear beneficiary of the stronger‑than‑expected Medicare Advantage rate decision, underpinning near‑term revenue and profitability improvements versus prior street assumptions. 5 Stocks That Should Benefit from the 2026 Medicare Advantage Rate Decision
• Positive Sentiment: Investor commentary and a bullish Seeking Alpha piece call the new Medicare payments a “gift,” arguing ELV’s valuation looks compelling after a significant pullback and technicals suggest a potential bottom. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
• Positive Sentiment: BofA upgraded its managed‑care outlook and raised Elevance’s price target, signaling analyst confidence that the policy change and underlying fundamentals support higher valuation. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Neutral Sentiment: Deeper analyses unpack how the Medicare rate bump flows through to profit — benefits to revenue are clear but the magnitude depends on membership trends, benefit cost ratios and risk‑adjustment implementation. Medicare Rates Up – What This Really Means For Elevance
• Neutral Sentiment: General market coverage notes health‑insurer peers are rallying on the CMS decision; this is a sector move that benefits ELV but individual execution still matters. Health insurance stocks are soaring on a Medicare update. Here’s what you need to know.
• Neutral Sentiment: Coverage previews and leadership commentary flag a recent executive shuffle focused on government programs; the market will watch whether management changes accelerate government business execution. Will Elevance Health’s (ELV) Leadership Shuffle Refocus Its Core Advantage In Government Programs?
• Negative Sentiment: Other pieces urge caution, noting ELV’s shares have fallen ~27% over the past year and that membership declines, higher benefit expense ratios and conservative guidance still pose risks despite the rate boost. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide
• Neutral Sentiment: An earnings preview highlights the items investors should watch in the next report (membership trends, benefit expense and guidance cadence) that will determine whether the positive policy news translates into sustainable EPS upside. Elevance Health earnings preview: What to expect

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ELV shares. Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Truist Financial decreased their price objective on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a report on Tuesday, February 3rd. Finally, Jefferies Financial Group cut their price objective on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Stock Performance

ELV opened at $311.22 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market cap of $68.36 billion, a price-to-earnings ratio of 12.39, a PEG ratio of 1.65 and a beta of 0.49. The company’s 50 day moving average is $312.98 and its 200 day moving average is $332.28. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter last year, the firm posted $3.84 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were issued a $1.72 dividend. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.2%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.